Dual MTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2015 Jul 3

PMID 26134944

Citations 29

Authors

Anupam Mitra

Jesus I Luna

Alina I Marusina

Alexander Merleev

Smriti Kundu-Raychaudhuri

David Fiorentino

Siba P Raychaudhuri

Emanual Maverakis

Affiliations

Soon will be listed here.

Citing Articles

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.

Son B, Lee W, Kim H, Shin H, Park H Cell Death Dis. 2024; 15(9):696.

PMID: 39349424 PMC: 11442590. DOI: 10.1038/s41419-024-07077-8.

Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis.

Zhou Y, Ling T, Shi W Respir Res. 2024; 25(1):245.

PMID: 38886743 PMC: 11184855. DOI: 10.1186/s12931-024-02878-z.

Redox Pathogenesis in Rheumatic Diseases.

Laniak O, Winans T, Patel A, Park J, Perl A ACR Open Rheumatol. 2024; 6(6):334-346.

PMID: 38664977 PMC: 11168917. DOI: 10.1002/acr2.11668.

Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.

Murphy S, Atienza J, Brown J, Cheruvallath Z, Cukierski M, Fabrey R ACS Med Chem Lett. 2023; 14(11):1544-1550.

PMID: 37970587 PMC: 10641921. DOI: 10.1021/acsmedchemlett.3c00351.

Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.

Driva T, Schatz C, Haybaeck J Biomolecules. 2023; 13(8).

PMID: 37627318 PMC: 10452661. DOI: 10.3390/biom13081253.

References

Lang W, Sandoval J . Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis. J Biomol Screen. 2014; 19(9):1235-45. DOI: 10.1177/1087057114545650. View

Bhattacharyya S, Wei J, Varga J . Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011; 8(1):42-54. PMC: 3954787. DOI: 10.1038/nrrheum.2011.149. View

Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F . Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010; 62(8):2476-87. DOI: 10.1002/art.27498. View

Bhagwat S, Gokhale P, Crew A, Cooke A, Yao Y, Mantis C . Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011; 10(8):1394-406. DOI: 10.1158/1535-7163.MCT-10-1099. View

Ong C, Khoo Y, Mukhopadhyay A, Do D, Lim I, Aalami O . mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. 2007; 16(5):394-404. DOI: 10.1111/j.1600-0625.2007.00550.x. View

Luna J, Ciriza J, Garcia-Ojeda M, Kong M, Herren A, Lieu D . Multiscale biomimetic topography for the alignment of neonatal and embryonic stem cell-derived heart cells. Tissue Eng Part C Methods. 2011; 17(5):579-88. DOI: 10.1089/ten.TEC.2010.0410. View

Sargent J, Milano A, Bhattacharyya S, Varga J, Connolly M, Chang H . A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2009; 130(3):694-705. PMC: 3867816. DOI: 10.1038/jid.2009.318. View

Gay S, Jones Jr R, Huang G, Gay R . Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989; 92(2):301-3. DOI: 10.1111/1523-1747.ep12276895. View

Fried L, Kirsner R, Bhandarkar S, Arbiser J . Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol. 2008; 6(3-4):217-9. PMC: 2705917. DOI: 10.1089/lrb.2008.1006. View

10.

Su T, Khanna D, Furst D, Danovitch G, Burger C, Maranian P . Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 2009; 60(12):3821-30. PMC: 2841149. DOI: 10.1002/art.24986. View

11.

Tamaki Z, Asano Y, Kubo M, Ihn H, Tada Y, Sugaya M . Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. J Dermatol Sci. 2014; 74(3):251-9. DOI: 10.1016/j.jdermsci.2014.02.002. View

12.

Datta-Mitra A, Mitra A, Ray R, Raychaudhuri S, Kundu-Raychaudhuri S . 1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. Int Immunopharmacol. 2013; 17(3):744-51. DOI: 10.1016/j.intimp.2013.08.009. View

13.

Raychaudhuri S, Raychaudhuri S . mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target. Indian J Dermatol. 2014; 59(1):67-70. PMC: 3884931. DOI: 10.4103/0019-5154.123499. View

14.

Abraham D, Eckes B, Rajkumar V, Krieg T . New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep. 2007; 9(2):136-43. DOI: 10.1007/s11926-007-0008-z. View